secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-060693
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen Q3 2023 net loss $23.3M; cash $129.5M; FDA clears FREEDOM-DM1 study in US
--------------------------------------------------------------------------------

- Net loss of $23.3M for Q3 2023, vs $18.6M in Q3 2022; R&D expenses $20.5M.
- Cash and cash equivalents $129.5M as of Sept 30, 2023; runway expected into 2025.
- FDA lifted clinical hold on FREEDOM-DM1 Phase 1 study; target doses 5, 10, 20 mg/kg.
- FDA granted Orphan Drug Designation to PGN-EDODM1 for myotonic dystrophy type 1.
- Anticipates proof-of-concept data from CONNECT1-EDO51 study in mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023060693/0000950170-23-060693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023060693/pepg-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer